Results 171 to 180 of about 136,011 (340)

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial

International Journal of Cancer, EarlyView.
What's New? Hyperprogressive disease (HPD) is defined by unusually rapid tumor growth following treatment initiation. In hepatocellular carcinoma (HCC), HPD is suspected of occurring more commonly with immune checkpoint inhibitors (ICIs), particularly when used as monotherapy, than with other treatment strategies.
Yuan Gao, Ann‐Lii Cheng, Lee X. Li, Natalie Parent, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich   +8 more
wiley   +1 more source

Multiparametric MRI and [18F]fluorodeoxyglucose positron emission tomography imaging is a potential prognostic imaging biomarker in recurrent glioblastoma [PDF]

, 2017
Purpose/objectivesMultiparametric advanced MR and [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging may be important biomarkers for prognosis as well for distinguishing recurrent glioblastoma multiforme (GBM) from treatment-related
Akash Sharma, Anupama Chundury, Christina I. Tsien, Comron Hassanzadeh, Comron Hassanzadeh, Jackson Rowe, Joseph E. Ippolito, Joseph E. Ippolito, Maria Rosana Ponisio, Michelle Miller-Thomas, Yuan James Rao   +10 more
core   +3 more sources

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

JAMA Oncology, 2019
Importance To date, single-agent programmed cell death 1 protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer. Combination strategies of PD-1/PD-L1 inhibition with
Joyce F. Liu, C. Herold, K. Gray, R. Penson, N. Horowitz, P. Konstantinopoulos, Cesar M. Castro, S. Hill, J. Curtis, W. Luo, U. Matulonis, S. Cannistra, D. Dizon   +12 more
semanticscholar   +1 more source

Real‐world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort

International Journal of Cancer, EarlyView.
What's New? The treatment landscape of metastatic colorectal cancer has evolved into a continuum of care with guideline recommendations depending on molecular status. However, guidelines are primarily based on the results of randomized clinical trials, which do not fully align with clinical practice.
Sietske C. M. W. van Nassau, Koen Zwart, Frederieke H. van der Baan, Geraldine R. Vink, Marloes A. G. Elferink, Petur Snaebjornsson, Anne M. May, Miriam Koopman, Jeanine M. L. Roodhart   +8 more
wiley   +1 more source

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity

Therapeutic Advances in Medical Oncology, 2010
The addition of bevacizumab to currently available treatment options for metastatic colorectal cancer has changed the traditional chemotherapy-based paradigm.
G. Chong, N.C. Tebbutt
doaj   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, EarlyView.
What's New? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Systemic platinum‐based chemotherapy is the first‐line treatment of choice for metastatic cervical cancer. While subsequent radiotherapy after primary chemotherapy is a potential option, its benefit remains unclear. This multicenter retrospective study aimed to evaluate whether post‐chemotherapy radiotherapy improves the prognosis of
Ai Miyoshi, Fumiaki Isohashi, Makoto Fujii, Tadashi Iwamiya, Masahiko Takemura, Yoshikazu Nagase, Takeshi Yokoi, Emi Yoshioka, Kimihiko Ito, Eri Yamabe, Kanji Masuhara, Tomoko Tsujie, Tadashi Kimura, Michiko Kodama   +13 more
wiley   +1 more source

Nuclear localization of the mitochondrial factor HIGD1A during metabolic stress. [PDF]

, 2013
Cellular stress responses are frequently governed by the subcellular localization of critical effector proteins. Apoptosis-inducing Factor (AIF) or Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH), for example, can translocate from mitochondria to the ...
Aghi, Manish, Ameri, Kurosh, Choi, Hwa J, Delay, Michael, Donne, Matthew, Jahangiri, Arman, Jeffrey, Stefanie S, Maltepe, Emin, Nguyen, Vien, Rajah, Anthony M, Rinaudo, Paolo F, Rowitch, David H, Sanders, Timothy A, Tormos, Kathryn V, Yeghiazarians, Yerem   +14 more
core   +2 more sources

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, EarlyView.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source